Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > Articoli online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 Oct 07



Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 Oct 07

Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer

Kruse V. 1, Van de Wiele C. 2, 4, Maes A. 4, 5, Borms M. 3, Pottel H. 5, Van Belle S. 1, Cocquyt V. 1

1 Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium;
2 Department of Radiology and Nuclear Medicine, University Ghent, Ghent, Belgium;
3 Department of Radiotherapy and Medical Oncology, AZ Groeninge, Kortrijk, Belgium;
4 Department of Nuclear medicine, AZ Groeninge, Kortrijk, Belgium;
5 Subfaculty of Medicine, Catholic University Leuven, Campus Kortrijk, Belgium

PURPOSE: To assess whether outcome in advanced breast cancer patients is related to metabolic response to endocrine therapy determined by FDG-PET.
METHODS: We retrospectively identified 21 consecutive breast cancer patients receiving endocrine therapy for metastatic disease (number of previous therapies 3.6 ±3.5; mean ±SD). All patients had been evaluated with at least 2 FDG-PET’s. The first scan was performed by initiation of endocrine therapy. The second scan was performed after a mean of 3.8 ±1.14 months (m). Seventy-two FDG-avid lesions were identified and followed. The mean change in SUVmax (ΔSUVmax) was calculated per patient.
RESULTS: ΔSUVmax dichotomized using the group median as cut-off (8.6%) was predictive of progression free survival (PFS). The median PFS for the response-group (n=10, median ΔSUVmax -20.9%) was 10.1 m. The median PFS for the progressive disease-group (n = 11, median ΔSUVmax 40.6%) was 6.7 m (log-rank testing p = 0.033).
CONCLUSIONS: Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG PET have a longer PFS when compared to non-responders. This finding is new, supporting the value of endocrine therapy among patients with advanced breast cancer.

lingua: Inglese


inizio pagina